22 September 2021 - Today, the U.S. FDA amended the emergency use authorisation for the Pfizer-BioNTech COVID-19 vaccine to allow for use of a single booster dose, to be administered at least six months after completion of the primary series in certain people.

These certain people are:

• individuals 65 years of age and older
• individuals 18 through 64 years of age at high risk of severe COVID-19
• individuals 18 through 64 years of age whose frequent institutional or occupational exposure to SARS-CoV-2 puts them at high risk of serious complications of COVID-19 including severe COVID-19

Today’s authorisation applies only to the Pfizer-BioNTech COVID-19 vaccine.

Read FDA press release